ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.031,58
-0,05%
S&P 500
5.283,40
0,11%
US Dollar vs BRL
5,2511
0,01%
Bitcoin
68.954,17
0,22%
Brent Oil
77,095
-1,34%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Taysha Gene Therapies Inc (TSHA)

  7. Taysha Gene Therapies Inc (TSHA) Notícias

TSHA

Taysha Gene Therapies (TSHA)

Taysha Gene Therapies Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TSHA
DataHoraFonteTítuloCódigoCompanhia
31/05/202417:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSHATaysha Gene Therapies Inc
30/05/202417:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSHATaysha Gene Therapies Inc
14/05/202417:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSHATaysha Gene Therapies Inc
14/05/202417:01GlobeNewswire Inc.Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:TSHATaysha Gene Therapies Inc
07/05/202417:05GlobeNewswire Inc.Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14NASDAQ:TSHATaysha Gene Therapies Inc
03/05/202417:05GlobeNewswire Inc.Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TSHATaysha Gene Therapies Inc
02/05/202409:00GlobeNewswire Inc.Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
20/03/202414:30AllPennyStocks.comAnother Biotech Steals The Show Following Major Clinical Data ReleaseNASDAQ:TSHATaysha Gene Therapies Inc
19/03/202417:01GlobeNewswire Inc.Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:TSHATaysha Gene Therapies Inc
19/03/202408:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:TSHATaysha Gene Therapies Inc
14/03/202417:26GlobeNewswire Inc.Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19NASDAQ:TSHATaysha Gene Therapies Inc
29/02/202410:00GlobeNewswire Inc.Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
15/02/202418:01GlobeNewswire Inc.Taysha Gene Therapies Provides Update on Deprioritized Pipeline ProgramsNASDAQ:TSHATaysha Gene Therapies Inc
09/02/202418:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TSHATaysha Gene Therapies Inc
22/01/202410:00GlobeNewswire Inc.Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual ConferenceNASDAQ:TSHATaysha Gene Therapies Inc
10/01/202410:00GlobeNewswire Inc.Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
20/12/202318:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSHATaysha Gene Therapies Inc
19/12/202309:30PR Newswire (US)Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene TherapiesNASDAQ:TSHATaysha Gene Therapies Inc
29/11/202310:00GlobeNewswire Inc.Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome PatientsNASDAQ:TSHATaysha Gene Therapies Inc
14/11/202318:08GlobeNewswire Inc.Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:TSHATaysha Gene Therapies Inc
07/11/202310:00GlobeNewswire Inc.Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14NASDAQ:TSHATaysha Gene Therapies Inc
03/11/202317:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TSHATaysha Gene Therapies Inc
24/10/202309:00GlobeNewswire Inc.Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual CongressNASDAQ:TSHATaysha Gene Therapies Inc
10/10/202309:00GlobeNewswire Inc.Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual CongressNASDAQ:TSHATaysha Gene Therapies Inc
05/10/202308:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:TSHATaysha Gene Therapies Inc
26/09/202309:00GlobeNewswire Inc.Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
21/09/202317:01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:TSHATaysha Gene Therapies Inc
19/09/202317:52Dow Jones NewsTaysha Gene Therapies to End Development of TSHA-120 After FDA FeedbackNASDAQ:TSHATaysha Gene Therapies Inc
19/09/202317:01GlobeNewswire Inc.Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)NASDAQ:TSHATaysha Gene Therapies Inc
11/09/202317:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TSHATaysha Gene Therapies Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TSHA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
OIBR3
OI ON
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados